Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Naltrexone for Methamphetamine Addiction

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
John Mendelson, MD, California Pacific Medical Center Research Institute
ClinicalTrials.gov Identifier:
NCT00984360
First received: September 14, 2009
Last updated: May 29, 2013
Last verified: May 2013

September 14, 2009
May 29, 2013
September 2009
July 2011   (final data collection date for primary outcome measure)
MA (-) Urine Samples [ Time Frame: Twice weekly for 5 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00984360 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Study of Naltrexone for Methamphetamine Addiction
A Pilot Trial of Naltrexone for Methamphetamine Addiction - Role of the A118G SNP

The purpose of this study is to determine whether methamphetamine-dependent individuals will use less methamphetamine when treated with naltrexone. The study will also investigate whether individuals with the mu opioid receptor gene variant A118G will use less methamphetamine than individuals without A118G.

Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Methamphetamine Dependence
Drug: Naltrexone
380mg extended-release, given once by intramuscular gluteal injection
Other Names:
  • Vivitrol
  • Vivitrex
  • Experimental: A118G
    Intervention: Drug: Naltrexone
  • Experimental: Wild-type
    Intervention: Drug: Naltrexone
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
22
September 2012
July 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age between 18 and 50 years
  • Patient is agreeable to conditions of study and signs consent form
Both
18 Years to 50 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00984360
1R01DA027161-01
Yes
John Mendelson, MD, California Pacific Medical Center Research Institute
California Pacific Medical Center Research Institute
Not Provided
Principal Investigator: John Mendelson, MD California Pacific Medical Center
California Pacific Medical Center Research Institute
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP